Farid Menaa
Fluorotronics, Inc and Californian Innovation Corp
USA
Title: Graphene-based technologies for detection of biomarkers of disease: The future is here!
Biography
Biography: Farid Menaa
Abstract
Graphene (G) and graphene-based derivatives (e.g. graphene oxide, hybrid nanocomposites) represent promising nanomaterials for the current and upcoming biosensor generations. Graphene and derivatives’ biosensing platforms can be used to monitor various molecules (e.g. proteins and its modifications, DNA and genomic alterations, glucose, ions, toxins) and cells (e.g. cancer cells, cancer stem cells). Interestingly, the qualitative and quantitative detection of proteinic biomarkers of diseases using graphene-based platforms (e.g. immunodiagnosis, bioimaging) is an emerging concept due to graphene’s unique intrinsic (i.e. physicochemical, structural) and tunable properties (i.e. surface functionalizations). Furthermore, it is possible now to manufacture reliable (i.e. in terms of sensitivity, stability, specificity, selectivity, rapidity) biophotonic sensing platforms, (e.g. Field Effect Transistors (FET), Fluorescence Resonance Energy Transfer (FRET) or Chemiluminescence Resonance Energy Transfer (CRET)). Eventually, G is eco-friendly and cost-effective in its use, contributing to its sustainable development for translational and personalized medicine. However, only a limited number of studies assessed the relative toxicity of G and derivatives in-vivo. My speech will focus and discuss graphene-based platforms for protein (e.g. thrombin, dopamine, CEA, EpCAM, PSA, BRCA1, phospho-p53, MMPs) detection, characterization and theranostic (i.e. disease diagnosis and therapy) applications.